Pfizer’s shot at the obesity‑drug crown: Can it still beat Novo Nordisk?

In the high‑stakes race for weight‑loss drugs, Pfizer Inc. isn’t out of the ring yet—even as Novo Nordisk A/S swings hard and fast. Novo threw down a $9 billion unsolicited bid for biotech Metsera Inc., already under agreement with Pfizer for roughly $7.3 billion. Pfizer has filed suit to block Novo’s approach, arguing the deal violates its merger rights and represents anti‑competitive behaviour. Behind the drama is the booming obesity‑treatment market, driven by GLP‑1 and next‑gen injectables. Metsera’s pipeline offers a potential monthly injection that could rival the stars from Novo and Eli Lilly & Co.. With Pfizer facing patent cliffs and COVID‑era revenue fade, securing Metsera could buy it a path back into growth. Novo, meanwhile, is speeding up under its new CEO but may have overreached. In this duel, Pfizer still has leverage—its deal terms give it a deadline to counter‑bid, and its courts fight may force Novo to pause. If Pfizer raises its offer or renegotiates, it could reclaim the narrative. But the clock is ticking, and the prize is a slice of one of pharma’s hottest markets. #SlimScan #GrowthStocks #CANSLIM